Author response to Colle et al

The event of pseudoprogression is rare in patients with MSI-high metastatic colorectal cancer receiving immune checkpoint inhibitors. In this response to the Letter to the Editor by Colle et al, we highlight that the timing of disease re-assessment may influence the incidence of pseudoprogression, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Fucà, Giovanni, Corti, Francesca, Pietrantonio, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231051/
https://www.ncbi.nlm.nih.gov/pubmed/34162717
http://dx.doi.org/10.1136/jitc-2021-003138
_version_ 1783713341690085376
author Fucà, Giovanni
Corti, Francesca
Pietrantonio, Filippo
author_facet Fucà, Giovanni
Corti, Francesca
Pietrantonio, Filippo
author_sort Fucà, Giovanni
collection PubMed
description The event of pseudoprogression is rare in patients with MSI-high metastatic colorectal cancer receiving immune checkpoint inhibitors. In this response to the Letter to the Editor by Colle et al, we highlight that the timing of disease re-assessment may influence the incidence of pseudoprogression, with early assessments being associated with higher incidence. Such dynamics should be considered when interpreting the efficacy of treatment.
format Online
Article
Text
id pubmed-8231051
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-82310512021-07-09 Author response to Colle et al Fucà, Giovanni Corti, Francesca Pietrantonio, Filippo J Immunother Cancer Commentary The event of pseudoprogression is rare in patients with MSI-high metastatic colorectal cancer receiving immune checkpoint inhibitors. In this response to the Letter to the Editor by Colle et al, we highlight that the timing of disease re-assessment may influence the incidence of pseudoprogression, with early assessments being associated with higher incidence. Such dynamics should be considered when interpreting the efficacy of treatment. BMJ Publishing Group 2021-06-23 /pmc/articles/PMC8231051/ /pubmed/34162717 http://dx.doi.org/10.1136/jitc-2021-003138 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Commentary
Fucà, Giovanni
Corti, Francesca
Pietrantonio, Filippo
Author response to Colle et al
title Author response to Colle et al
title_full Author response to Colle et al
title_fullStr Author response to Colle et al
title_full_unstemmed Author response to Colle et al
title_short Author response to Colle et al
title_sort author response to colle et al
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231051/
https://www.ncbi.nlm.nih.gov/pubmed/34162717
http://dx.doi.org/10.1136/jitc-2021-003138
work_keys_str_mv AT fucagiovanni authorresponsetocolleetal
AT cortifrancesca authorresponsetocolleetal
AT pietrantoniofilippo authorresponsetocolleetal

Ejemplares similares